Horizon Discovery, a PerkinElmer company, drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine. With more than a decade of experience in the engineering of cell lines, Horizon offers innovative tools and services based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines Horizon is headquartered in Cambridge, UK with offices in USA and Japan.
Go to our website: horizondiscovery.com/
Latest Protocols and Applications
This is an abbreviated protocol for transfecting Edit-R™ Cas9 mRNA (Cat #CAS11195, #CAS11859, or #CAS11860) with synthetic guide RNA into cultured mammalian cells using DharmaFECT™ Duo transfection reagent (Cat #T-2010-xx). Synthetic guide RNA can be either synthetic single guide RNA, or synthetic c... More